These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 355881)

  • 1. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.
    Freiman JA; Chalmers TC; Smith H; Kuebler RR
    N Engl J Med; 1978 Sep; 299(13):690-4. PubMed ID: 355881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How many do I need? Basic principles of sample size estimation.
    Devane D; Begley CM; Clarke M
    J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-inferiority trials: the 'at least as good as' criterion.
    Laster LL; Johnson MF
    Stat Med; 2003 Jan; 22(2):187-200. PubMed ID: 12520556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some issues in the design and interpretation of 'negative' clinical studies.
    Makuch RW; Johnson MF
    Arch Intern Med; 1986 May; 146(5):986-9. PubMed ID: 3963987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta, or type II error in psychiatric controlled clinical trials.
    Edlund MJ; Overall JE; Rhoades HM
    J Psychiatr Res; 1985; 19(4):563-7. PubMed ID: 4078759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer.
    Taylor KM; Margolese RG; Soskolne CL
    N Engl J Med; 1984 May; 310(21):1363-7. PubMed ID: 6717508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation in flexible two stage designs.
    Brannath W; König F; Bauer P
    Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to assess the size of a clinical trial?].
    Paesmans M
    Rev Mal Respir; 1994; 11(6):547-57. PubMed ID: 7831504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure.
    Wilson DP
    Clin Trials; 2010 Feb; 7(1):36-43. PubMed ID: 20007407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reporting on methods in clinical trials.
    DerSimonian R; Charette LJ; McPeek B; Mosteller F
    N Engl J Med; 1982 Jun; 306(22):1332-7. PubMed ID: 7070458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimization of sample size when comparing two small probabilities in a non-inferiority safety trial.
    de Boo TM; Zielhuis GA
    Stat Med; 2004 Jun; 23(11):1683-99. PubMed ID: 15160402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial design for assessing noninferiority when superiority is expected.
    Freidlin B; Korn EL; George SL; Gray R
    J Clin Oncol; 2007 Nov; 25(31):5019-23. PubMed ID: 17971602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials.
    Diehr P; Chen L; Patrick D; Feng Z; Yasui Y
    Contemp Clin Trials; 2005 Feb; 26(1):45-58. PubMed ID: 15837452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The delta and epsilon errors in the assessment of cancer clinical trials.
    Staquet MJ; Rozencweig M; Von Hoff DD; Muggia FM
    Cancer Treat Rep; 1979; 63(11-12):1917-21. PubMed ID: 526924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.